NCT01501760View on ClinicalTrials.gov

Efficacy and Safety Study of Avastin to Treat Neovascularisation of the Cornea

PHASE3CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

May 13, 2012

Primary Completion Date

October 31, 2019

Study Completion Date

October 31, 2019

Conditions
Corneal Newvessels
Interventions
DRUG

bevacizumab

Three subconjunctival injections of 0.5 ml of bevacizumab at: inclusion, 1 month, 2 month

DRUG

NaCl

Three subconjunctival injections 0.5 ml placebo (Balanced salt) solution at inclusion, 1 month, 2month

Trial Locations (5)

31059

CHU de Toulouse, Service d'Ophtalmologie, Toulouse

67000

CHU Strasbourg- Service Ophtalmlogie, Strasbourg

86021

CHU Poitiers-Ophtalmologie, Poitiers

87042

Service d'Ophtalmologie, Limoges

Unknown

CHU St Etienne, Saint-Etienne

All Listed Sponsors
lead

University Hospital, Limoges

OTHER

NCT01501760 - Efficacy and Safety Study of Avastin to Treat Neovascularisation of the Cornea | Biotech Hunter | Biotech Hunter